Kavita Y Sarin

List of Publications by Year
in descending order

112 papers	4,699 citations	172457 29 h-index	110387 64 g-index
118 all docs	118 docs citations	118 times ranked	8020 citing authors

#	Article	IF	Citations
1	Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2022, 142, 382-389.	0.7	7
2	Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat. JAMA Dermatology, 2022, 158, 105.	4.1	3
3	Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 2022, 87, 573-581.	1.2	5
4	Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment. Science Advances, 2022, 8, .	10.3	16
5	ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1. Life Science Alliance, 2022, 5, e202101353.	2.8	8
6	Fitzpatrick phototype disparities in identification of cutaneous malignancies by Google Reverse Image. Journal of the American Academy of Dermatology, 2021, 84, 1415-1417.	1.2	3
7	Prevalence and risk factors for high-frequency basal cell carcinoma in the United States. Journal of the American Academy of Dermatology, 2021, 84, 1493-1495.	1.2	2
8	A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. Journal of the American Academy of Dermatology, 2021, 84, 1160-1162.	1.2	10
9	Loss-of-Function Variants in the Tumor-Suppressor Gene <i>PTPN14</i> Confer Increased Cancer Risk. Cancer Research, 2021, 81, 1954-1964.	0.9	15
10	Journal attitudes and outcomes of preprints in dermatology. British Journal of Dermatology, 2021, 185, 230-232.	1.5	1
11	Prevalence of potentially allergenic ingredients in products labeled for eczema care. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
12	691 Neutrophil and C5aR dynamics in hidradenitis suppurativa disease progression. Journal of Investigative Dermatology, 2021, 141, S120.	0.7	0
13	487 Topical MEK inhibition as precision targeted chemoprevention. Journal of Investigative Dermatology, 2021, 141, S84.	0.7	0
14	Automated detection of skin reactions in epicutaneous patch testing using machine learning. British Journal of Dermatology, 2021, 185, 456-458.	1.5	2
15	Dermatology Advances Into an Era of Precision Medicine. JAMA Dermatology, 2021, 157, 770-772.	4.1	1
16	Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts. JAAD International, 2021, 3, 42-52.	2.2	24
17	Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. Cancers, 2021, 13, 3870.	3.7	14
18	Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. Neurology, 2021, 97, S42-S49.	1.1	2

#	Article	IF	Citations
19	Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4717-4725.	7.0	9
20	Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. JCI Insight, 2021, 6, .	5.0	10
21	Direct-to-consumer genetic risk scoring for melanoma improves adherence to sun-protective behaviors among increased-risk groups: Results from a prospective United States cohort study. Journal of the American Academy of Dermatology, 2021, 85, 1035-1038.	1.2	0
22	Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis. Journal of the American Academy of Dermatology, 2020, 82, 753-754.	1.2	11
23	Comparing online engagement and academic impact of dermatology research: An Altmetric Attention Score and PlumX Metrics analysis. Journal of the American Academy of Dermatology, 2020, 83, 648-650.	1.2	15
24	Ways to Improve Care for LGBT Patients in Dermatology Clinics. Dermatologic Clinics, 2020, 38, 269-276.	1.7	5
25	AP-1 and TGFÃŸ cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma. Nature Communications, 2020, 11, 5079.	12.8	47
26	18811 Crowdfunding for the treatment of cutaneous malignancies: Trends, correlates, and money raised. Journal of the American Academy of Dermatology, 2020, 83, AB107.	1.2	1
27	Angular compounding for speckle reduction in optical coherence tomography using geometric image registration algorithm and digital focusing. Scientific Reports, 2020, 10, 1893.	3.3	8
28	Sexual and Gender Minority Curricula Within US Dermatology Residency Programs. JAMA Dermatology, 2020, 156, 593.	4.1	14
29	Gamification improves melanoma visual identification among high school students: Results from a randomized study. Pediatric Dermatology, 2020, 37, 752-753.	0.9	11
30	Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma. Nature Communications, 2020, 11, 820.	12.8	30
31	Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry. JCI Insight, 2020, 5, .	5.0	17
32	Patient Crowdfunding for the Treatment of Cutaneous Malignancies. Dermatologic Surgery, 2020, Publish Ahead of Print, 1012-1013.	0.8	1
33	Response to Shih etÂal.. Journal of Investigative Dermatology, 2019, 139, 2385-2386.	0.7	0
34	Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas. JAMA Dermatology, 2019, 155, 1078.	4.1	21
35	Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine, 2019, 25, 1251-1259.	30.7	974
36	Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. Journal of Investigative Dermatology, 2019, 139, 2263-2271.e5.	0.7	24

#	Article	IF	Citations
37	Assessment of readability and content of patientâ€initiated google search results for epidermolysis bullosa. Pediatric Dermatology, 2019, 36, 1004-1006.	0.9	4
38	Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment. Dermatologic Surgery, 2019, 45, 608-610.	0.8	2
39	Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. Pigment Cell and Melanoma Research, 2019, 32, 474-478.	3.3	1
40	Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. Journal of Investigative Dermatology, 2019, 139, 1439-1448.	0.7	38
41	Alterations of the MEK/ERK, BMP, and Wnt/Î²-catenin pathways detected in the blood of individuals with lymphatic malformations. PLoS ONE, 2019, 14, e0213872.	2.5	10
42	533 Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. Journal of Investigative Dermatology, 2019, 139, S92.	0.7	0
43	From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB) . Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 933-942.	1.8	15
44	Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology, 2019, 80, 564-566.	1.2	83
45	Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care. Seminars in Cutaneous Medicine and Surgery, 2019, 38, E57-E63.	1.6	8
46	Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection. JMIR Public Health and Surveillance, 2019, 5, e11264.	2.6	26
47	Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning. JAMA Oncology, 2018, 4, 581.	7.1	9
48	Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. Journal of the American Academy of Dermatology, 2018, 79, 36-41.e10.	1.2	22
49	Noncanonical hedgehog pathway activation through SRFâ€“MKL1 promotes drug resistance in basal cell carcinomas. Nature Medicine, 2018, 24, 271-281.	30.7	82
50	Genomic Stability in Syndromic Basal CellÂCarcinoma. Journal of Investigative Dermatology, 2018, 138, 1044-1051.	0.7	20
51	Identification of Atorvastatin for Moderate toÂSevere Hidradenitis through Drug Repositioning Using Public Gene ExpressionÂDatasets. Journal of Investigative Dermatology, 2018, 138, 1209-1212.	0.7	3
52	Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk. Journal of Investigative Dermatology, 2018, 138, 2072-2075.	0.7	20
53	Referred by Google: mining Google Trends data to identify patterns in and correlates to searches for dermatological concerns and providers. British Journal of Dermatology, 2018, 178, 794-795.	1.5	3
54	Azathioprine and risk of multiple keratinocyte cancers. Journal of the American Academy of Dermatology, 2018, 78, 27-28.e1.	1.2	17

#	Article	IF	Citations
55	Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI Insight, 2018, 3, .	5.0	23
56	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of <i>BAP1</i> and Other Germline Mutations. Journal of Clinical Oncology, 2018, 36, 3485-3494.	1.6	104
57	Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014. Journal of the American Academy of Dermatology, 2018, , .	1.2	3
58	Automated Classification of Skin Lesions: From Pixels to Practice. Journal of Investigative Dermatology, 2018, 138, 2108-2110.	0.7	76
59	248 Early detection of chemotherapeutic skin toxicities in social health networks using deep learning. Journal of Investigative Dermatology, 2018, 138, S42.	0.7	0
60	TGFÎ², Fibronectin and Integrin Î±5Î²1 Promote Invasion in Basal Cell Carcinoma. Journal of Investigative Dermatology, 2018, 138, 2432-2442.	0.7	29
61	221 BCC to SCC pathway switching during tumor evolution and the role of the primary cilium. Journal of Investigative Dermatology, 2018, 138, S37.	0.7	0
62	164 Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. Journal of Investigative Dermatology, 2018, 138, S28.	0.7	2
63	Abstract LB-B32: Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKCi inhibitors. , 2018, , .		0
64	A survey of direct-to-consumer teledermatology services available to US patients: Explosive growth, opportunities and controversy. Journal of Telemedicine and Telecare, 2017, 23, 19-25.	2.7	36
65	Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk. Journal of the American Academy of Dermatology, 2017, 76, 829-835.e1.	1.2	7
66	Association between genetic variation within vitamin D receptorâ€DNA binding sites and risk of basal cell carcinoma. International Journal of Cancer, 2017, 140, 2085-2091.	5.1	11
67	Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1107-1113.	2.5	53
68	Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. Journal of the American Academy of Dermatology, 2017, 77, 233-234.e2.	1.2	9
69	Association study of genetic variation in <scp>DNA</scp> repair pathway genes and risk of basal cell carcinoma. International Journal of Cancer, 2017, 141, 952-957.	5.1	14
70	Health Cards by Google: dermatologist review of the inclusivity and utility of the medical search application. British Journal of Dermatology, 2017, 176, 1398-1400.	1.5	1
71	Basosquamous Carcinoma: Controversy, Advances, and Future Directions. Dermatologic Surgery, 2017, 43, 23-31.	0.8	32
72	Genetic diseases associated with an increased risk of skin cancer development in childhood. Current Opinion in Pediatrics, 2017, 29, 426-433.	2.0	17

#	Article	IF	Citations
73	Postzygotic Mutations in Beta-Actin Are Associated with Beckerâ€™s Nevus and Beckerâ€™s Nevus Syndrome. Journal of Investigative Dermatology, 2017, 137, 1795-1798.	0.7	38
74	Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. Journal of the American Academy of Dermatology, 2017, 76, 353-354.	1.2	28
75	Genetic variants associate with systemic lupus erythematosus risk across ethnic groups. British Journal of Dermatology, 2017, 177, 620-621.	1.5	0
76	137 SRF/MRTF drive basal cell carcinoma growth through hedgehog pathway activation. Journal of Investigative Dermatology, 2017, 137, S23.	0.7	0
77	IFNÎ³-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell, 2017, 170, 127-141.e15.	28.9	140
78	Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. Pediatric Dermatology, 2017, 34, e35-e36.	0.9	4
79	Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight, 2017, 2, .	5.0	49
80	Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. Oncotarget, 2017, 8, 17586-17592.	1.8	61
81	Identification of Alpha-Adrenergic Agonists asÂPotential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets. Journal of Investigative Dermatology, 2016, 136, 1517-1520.	0.7	14
82	Direct-to-consumer teledermatology services for pediatric patients: Room for improvement. Journal of the American Academy of Dermatology, 2016, 75, 887-888.	1.2	14
83	Assessment of Accuracy of Patient-Initiated Differential Diagnosis Generation by Google Reverse Image Searching. JAMA Dermatology, 2016, 152, 1164.	4.1	7
84	Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nature Communications, 2016, 7, 12048.	12.8	117
85	Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nature Communications, 2016, 7, 12510.	12.8	94
86	Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatology, 2016, 152, 452.	4.1	82
87	Familial skin cancer syndromes. Journal of the American Academy of Dermatology, 2016, 74, 437-451.	1.2	46
88	Familial skin cancer syndromes. Journal of the American Academy of Dermatology, 2016, 74, 423-434.	1.2	54
89	An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clinical Cancer Research, 2016, 22, 1325-1329.	7.0	115
90	Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLoS ONE, 2016, 11, e0168031.	2.5	13

#	Article	IF	Citations
91	The digital age of melanoma management: detection and diagnostics. Melanoma Management, 2015, 2, 383-391.	0.5	1
92	Core skin DC signatures control immune tolerance to skin cancer and limit anti-tumor immunity. , 2015, 3, P205.		1
93	Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. Journal of Investigative Dermatology, 2015, 135, 3197-3200.	0.7	20
94	Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma. Cancer Cell, 2015, 27, 327-341.	16.8	316
95	Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. Cancer Cell, 2015, 27, 342-353.	16.8	337
96	A Subdermal Source: Contact Dermatitis. American Journal of Medicine, 2015, 128, 578-581.	1.5	0
97	Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. Journal of Investigative Dermatology, 2015, 135, 2138-2141.	0.7	18
98	Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. Journal of Clinical Oncology, 2015, 33, 2692-2694.	1.6	12
99	Squamous Change in Basal-Cell Carcinoma with Drug Resistance. New England Journal of Medicine, 2015, 373, 1079-1082.	27.0	47
100	Activating HRAS Mutation in Nevus Spilus. Journal of Investigative Dermatology, 2014, 134, 1766-1768.	0.7	31
101	Dermatologic applications of direct-to-consumer genomic analysis. Journal of the American Academy of Dermatology, 2014, 71, 993-995.	1.2	2
102	Dermatomyositis associated with capecitabine in the setting of malignancy. Journal of the American Academy of Dermatology, 2014, 70, e47-e48.	1.2	11
103	Molecular Profiling to Diagnose a Case of Atypical Dermatomyositis. Journal of Investigative Dermatology, 2013, 133, 2796-2799.	0.7	6
104	Mosaic Activating RAS Mutations in Nevus Sebaceus and Nevus Sebaceus Syndrome. Journal of Investigative Dermatology, 2013, 133, 824-827.	0.7	55
105	Activating<i>HRAS</i>Mutation in Agminated Spitz Nevi Arising in a Nevus Spilus. JAMA Dermatology, 2013, 149, 1077.	4.1	45
106	Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nature Medicine, 2012, 18, 111-119.	30.7	103
107	Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab. Archives of Dermatology, 2012, 148, 990.	1.4	4
108	TERT Promotes Epithelial Proliferation through Transcriptional Control of a Myc- and Wnt-Related Developmental Program. PLoS Genetics, 2008, 4, e10.	3.5	283

#	Article	IF	Citations
109	Aging, Graying and Loss of Melanocyte Stem Cells. Stem Cell Reviews and Reports, 2007, 3, 212-217.	5.6	45
110	Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature, 2005, 436, 1048-1052.	27.8	383
111	TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genetics, 2005, preprint, e10.	3.5	0
112	Partnering with a senior living community to optimise teledermatology via full body skin screening during the COVIDâ€19 pandemic: A pilot programme. Skin Health and Disease, 0, , .	1.5	1